Skip to main content
. 2019 Mar 15;98(13):e14135. doi: 10.1097/MD.0000000000014135

Figure 4.

Figure 4

(A) Pooled analysis of grade 3/4 treatment-related adverse events; (B) subgroup analysis of grade 3/4 treatment-related adverse events by type of combination (C) subgroup analysis of grade 3/4 treatment-related adverse events by cancer type.